IndicationLiver diseases (injury, fibrosis, cirrhosis and cancer)
Oró D et al. J Hepatol. 2016
Liver fibrosis and cirrhosis induced by CCl4 in mouse and rat
- Investigation of signaling pathways and possible therapeutic targets involved in liver injury, inflammation, fibrosis and cancer.
- Investigation of the therapeutic effects of different nanoparticles and biomaterials (cerium, carbon and polymeric nanoparticles) on liver fibrosis and cancer.
- Investigation of the therapeutic effects of cell implants and tissue engineering on liver regeneration and fibrosis regression.
- Selective gene therapy or sh/siRNA gene silencing to macrophages, hepatocytes, and endothelial cells.
- Lipidomic studies using gas chromatography-mass spectrometry.
- Study of insulin resistance, obesity and hypertrigliceridemia,
- Hemodynamic studies (cardiac output, mean arterial and portal pressure).
- Study of hydrosaline balance, liver and renal function, and excretion.
- Vascular biology analyses: Angiography, lymphangiography, vascular permeability, retina angiogenesis and vascular casting in mouse and rat.
- Embryonic vascular assessment in mouse.
- Vascular casting in mouse and rat
- Measurement of vascular density in response to anti-angiogenic treatment.
Principal investigatorsWladimiro Jiménez, Pedro Melgar-Lesmes.
The use of these pre-clinical models allows evaluating the possible clinical applicability of new drugs or therapies using novel drugs, functionalized nanoparticles or biomaterials.